Solid Biosciences’ Post

🎉 Excited to Announce the Launch of the ImPRESS Trial Last week Tuesday, we officially launched the ImPRESS Trial—an innovative study investigating the use of epidural spinal cord stimulation (eSCS) to improve bladder and bowel function for individuals living with spinal cord injury (SCI). This research is addressing a critical priority for the SCI community. After an SCI, the disruption between the brain and pelvic organs often results in incontinence, constipation, and reduced quality of life. Through this trial, we aim to: -Relax overactive bladder and bowel function. -Facilitate controlled voiding. -Improve pelvic floor muscle control. This milestone was only possible thanks to an incredible collaboration with the following team: 👏 John Afolayan 👏 Lynsey Duffell 👏Manish Desai 👏 Dr. Sarah Knight 👏 Sean Doherty 👏 Dr. Hannah Houliston 👏 Ms. Natalia Vasquez 👏 Sister Evangeline Martinez 👏 Tacson Fernandez 👏 Prof. Anton Emmanuel 👏 Richard Nobrega 👏 Prof. Jalesh Panicker 👏 Prof. Ronaldo Ichiyama 👏 Dr. Dagmar Alber 👏 Dr. Mona Bajaj-Elliott 👏 Spinal Research 👏 Injured Jockeys Fund 👏 Nevro

With Theranostics, physicians specifically target what they see. The goal is to target the tumor selectively and spare the normal organs. For that, they need post treatment SPECT/CT with the highest quality imaging to review. StarGuide our 3D digital SPECT/CT supports nuclear medicine departments around the globe treating Theranostics patients. #worldTheranosticsday

Becker Education and Engagement Day is this Saturday! If you were not able to attend last year's BEED, it's not too late to gain valuable insights from Dr. Vandenborne's 2023 presentation: "Imaging Muscles in Becker Muscular Dystrophy." Learn more about how measuring muscle fat fraction helps inform clinical trials: https://lnkd.in/eRGVxswg #BeckerMuscularDystrophy

End of the EU-funded MeDiTATe project we have been working on in the last few years.

People with Duchenne muscular dystrophy (DMD) and their families can’t keep having to explain what it is. They need understanding and support. We recommend that the governments in each of the four nations should fund awareness campaigns to improve understanding of the range of neuromuscular conditions. You can read our other recommendations for improving awareness and understanding of DMD in our report, here: https://lnkd.in/ejWYMPdu #WDAD2024

Excited to share our newest publication, delving into the complex relationship between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in atherosclerosis development. Recognizing endothelial cells' critical role in frontline defense, this review signifies a new phase in comprehending how loss of endothelial identity impacts cell autophagy. Investigating the interplay between these phenomena urges us to rethink pharmacological strategies, not just for combating atherosclerosis, but also for addressing diverse vessel-related pathologies. https://lnkd.in/eer8PWa4

On March 31st, for World Theranostics Day, we celebrate how Theranostics is connecting healthcare. Theranostics isn't just about treating diseases; it's about treating individuals. By combining diagnostic and therapeutic tools, it enables personalized medicine, and helps improve accuracy and increase efficiency.. Our commitment to innovation extends beyond imaging capabilities. Through initiatives like the Solid Target Platform for our PETtrace cyclotron and the development of StarGuide , innovative digital SPECT/CT powered by CZT, and Omni Legend , digital PET/CT powered by Precision DL software. We’re helping revolutionizing the way clinicians diagnose and treat cancer, improving access to cutting-edge technology and personalized solutions. Let's recognize the impact of #Theranostics on healthcare and commit to advancing precision care for all. https://lnkd.in/ekW9-8TU #GEHealthCare #FutureofHealthcare #WorldTheranosticsDay #PrecisionHealthcare

As I leave Montreal and another Motor Neurone Disease (MND) Association annual meeting, I have mixed feelings that deserve two separate posts. First the positive:   There is a great deal of energy, excitement, and hope this year, and there are definite signs of progress. I'm always energized by the involvement of people living with ALS, and that involvement is growing year over year…kudos to the leadership of MNDA. I'm so grateful for time with friends new and old from the The International Alliance of ALS/MND Associations, ALS ONE, The ALS Association, Muscular Dystrophy Association, Genetic ALS & FTD: End the Legacy, and more. Cathy Cummings and Cathy Collet, Jean Swidler, Cassandra Haddad, Paula Trefiak, Tammy Moore, David Taylor, Nick Cole, Brian Dickie, Sharon Hesterlee, Kuldip Dave, and some additional people living with ALS and their families (I won't name you because I don't know whether you'd approve, but know I was so pleased to see you).   My academic friends and colleagues continue to inspire me with their work. I hate to name anyone in particular because I can't name everyone without writing a book, but just to put a face on something I find hopeful: Martin Turner's talk, and by extension the work of everyone at EXPERTS-ALS, were a showcase of how to learn from the past and move the field forward.   I don't want to go on too long in one go, so the takeaway from this post should be that there are many, many reasons to be hopeful and inspired in the ALS space.

They say it takes a village! That's precisely why we work closely with our State counterparts to deliver comprehensive support & positive outcomes across the nation. Together with Muscular Dystrophy QLD, Muscular Dystrophy Tasmania, Muscular Dystrophy NSW & Muscular Dystrophy Australia, we’re united in our mission to build a brighter future for the muscular dystrophy & neuromuscular community. We focus on: 1. Service Provision: Collaborating to ensure our community has access to high-quality, coordinated care. By combining our expertise, we aim to streamline service delivery, reducing barriers for individuals seeking help & making it easier to access necessary therapies & support systems. 2. Linking with Supports & Services: We are dedicated to connecting people affected by neuromuscular conditions with a wide range of available resources, from specialised medical care to emotional & practical support. We also advocate for improved access to essential therapies & ensure families receive the guidance they need to navigate their journey. 3. Investments in Research & Therapies: Advancing research is crucial to discovering new treatments & improving the lives of those with muscular dystrophy. By pooling our resources, we’re driving collaborative research initiatives & bringing innovative therapies and interventions to Australia. We stay at the forefront of medical advancements to ensure our community benefits from the latest & most effective treatments. 4. Social Programs & Connections: Building strong connections is essential for emotional & social well-being. We are committed to providing access to social programs that offer opportunities for individuals & families to come together, share experiences & support one another in a welcoming & inclusive environment. For Muscular Dystrophy Awareness Month 2024, we reaffirm our dedication to working collaboratively to create positive change for the muscular dystrophy & neuromuscular community in Australia. Together, we are stronger 💙

One more day to submit your short talk and poster abstracts #EASD2024!